EFFICIENCY OF THE USING THE PREPARATION URSOSAN FORTE BY SICK PEOPLEWITH METABOLIC SYNDROME
Keywords:
Metabolic syndrome, immune disorders, ursosan, cytokine statusAbstract
Introduction: Metabolic syndrome is a cluster of factors associated with an increased risk of atherosclerotic cardiovascular diseases and diabetes mellitus [4-17]. Currently, immune inflammation is considered one of the main factors in the development of cardiovascular pathology. An increase in inflammatory indicators such as interleukins (IL) -1 and 6, and tumor necrosis factor-α (TNF-α) is associated with a high risk of complications in cardiac pathology and is considered an immunological marker of cardiovascular risk [2].
The aim of our study was to investigate the levels of interleukins 6 and 17 in patients with metabolic syndrome before and after treatment with Ursosan forte.
Materials and methods: We examined the clinical and immunological parameters of 40 individuals, including 18 women and 22 men aged 25 to 55 years with a body mass index of 25.0 - 32.2 kg/m2, and 30 people in the control group of generally healthy individuals. Results: The conducted studies have established that in metabolic syndrome, activation of the cytokine system is observed, which is manifested by a multiple-fold increase in the serum levels of IL-6 and IL-17. It should be noted that in patients with metabolic syndrome both with and without hypertension, the levels of the studied cytokines were practically identical. The administered therapy had a positive effect on the cytokine status. In patients with a BMI greater than 30 kg/m2, the levels of IL-6 and IL-17 significantly exceeded the cytokine content in patients with a BMI up to 30 kg/m2. The therapy led to a decrease in IL-6 levels but did not significantly affect IL-17 levels.
References
Шварц В. Регуляция метаболических процессов интерлейкина 6. Журнал «Цитокины и воспаление»,№3,2019,с.3-10
Пирогова И.Ю., Яковлева С.В., Неуймина Т.В. и др. Плейотропные эффекты урсодезоксихолевой кислоты при неалкогольной жировой болезни печени и метаболическом синдроме. Consilium Medicum. 2019; 21 (8): 65–70. DOI: 10.26442/20751753.2019.8.190365
Танченко О.А., Нарышкины С.В., Сивякова О.Н. Урсодезоксихолевая кислота в комплексном лечении больных с метаболическим синдромом.Российский журнал гастроэнтерологии, гепатологии, колопроктологии,2012 22(1) 82-86 ISSN: 1382-4376eISSN: 2658-6673
Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity/// J Am SocNephrol – 2014 – 15: 2792–80
Халимова Х.М., Меметов Ф.Ю., Раимова М.М. Динамика показателей клетлчного т гуморального иммунитета у больных с ишемическим инсультом на фоне лечения «TAF»Лактофлором./ Вестник Казахского национального медицинского университета, №4,2015, с.232-233
Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report. Circulation 106, 3143-3421 (2012). The 2001 NCEP report sparked increased interest of the medical community in the metabolic syndrome. It led to new research as well as controversy about the clinical utility of the syndrome.
Grundy, S. M. et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433-438 (2014).
Grundy, S. M. et al. Clinical management of metabolic syndrome: report of the American Heart Association/ National Heart, Lung, and Blood Institute/ American Diabetes Association conference on scientific issues related to management. Circulation 109, 551-556 (2014).
Eckel, R. H., Grundy, S. M. &Zimmet, P. Z. The metabolic syndrome: epidemiology, mechanisms, and therapy. Lancet 365, 1415-1428 (2015). Reviews the worldwide epidemiology, pathophysiology and management of the metabolic syndrome.
Isomaa, B. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. DiabetesCare 24, 683-689 (2011).
Lakka, H. M. et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA 288, 2709-2716 (2012).
Sattar, N. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108, 414- 419 (2013).
Girman, C. J. et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex- CAPS). Am. J. Cardiol. 93, 136-141 (2014).
Malik, S. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1245–1250 (2014).
Olijhoek, J. K. et al. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur. Heart J. 25, 342–348 (2014).
Alexander, C. M. et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210-1214 (2013). Shows that most patients with type 2 diabetes have the metabolic syndrome, and the syndrome accounts for most of the increased risk for coronary heart disease resulting from diabetes.
Ninomiya, J. K. et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109, 42-46 (2014).
McNeill, A. M. et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. DiabetesCare 28, 385-390 (2015).
Solymoss, B. C. et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron. ArteryDis. 14, 207-212 (2013).
Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2015).
